Your flu shot could help design next Year's vaccine

NCT ID NCT04109222

Completed Knowledge-focused Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study collected blood samples from 90 children (6 months to under 9 years) and adults 65 and older after they received the 2019-2020 flu vaccine. The samples were sent to health agencies like the WHO and CDC to help them decide which flu strains to include in future vaccines. The study did not test a new treatment or cure, but aimed to improve vaccine recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fluzone Quadrivalent and Fluzone High-Dose influenza vaccines
What this could lead to: If successful, this study could help health experts choose the right flu vaccine formula for future seasons, potentially making flu shots more effective.
What could go wrong: This is a small, completed sample-collection study, not a test of vaccine effectiveness. The results may not directly improve vaccines or protect against flu.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA

Contacts and locations

Locations

Investigational Site Number 8400001

Salt Lake City, Utah, 84121, United States
Investigational Site Number 8400002

Bardstown, Kentucky, 40004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.